Pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancer

Journal of Clinical Pharmacology

Volumn 46, Issue 10, 2006, Pages 1116-1127

  Zhang, Steven ^a,f   Zannikos, Peter ^a   Awada, Ahmad ^b   Piccart Gebhart, Martine ^b   Dirix, Luc Y ^c   Fumoleau, Pierre ^d   Verhaeghe, Tom ^e   Francois, Marc ^e   De Porre, Peter ^e  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b JULES BORDET INSTITUTE   (Belgium)

^c AZ St Augustinus   (Belgium)

^d CENTRE GEORGES FRANÇOIS LECLERC   (France)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^f Centocor   (United States)

Author keywords

Intravenous infusion; Metabolite; Oral administration; Pharmacokinetics; Protein binding; Tipifarnib

Indexed keywords

DRUG METABOLITE; GLUCURONIDE; IMIDAZOLE; R 101763; R 104209; R 130525; TIPIFARNIB; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEALKYLATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GLUCURONIDATION; HEMATOLOGIC DISEASE; HUMAN; INFECTION; MALE; NAUSEA; NEUROPATHY; NEUTROPENIA; PHLEBITIS; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FEMALE; GLUCURONIDES; GLYCOPROTEINS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; PROTEIN BINDING; QUINOLONES; SERUM ALBUMIN; TABLETS; TREATMENT OUTCOME;

EID: 33748643781     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006291034     Document Type: Article

References (17)

1. Liesveld JL, Lancet JE, Rosell KE, et al. Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis. Leukemia. 2003;17:1806-1812.
2. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 2001;97:3361-3369.
3. End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001;61:131-137.
4. Lancet JE, Karp JE. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood. 2003;102:3880-3889.
5. Goemans BF, Zwaan CM, Huismans DR, et al. In-vitro sensitivity to the farnesyltransferase inhibitor R115777 of childhood acute myeloid (AML) and lymphoblastic leukemia (ALL) and normal bone marrow cells [abstract]. Blood. 2002;100:545a.
6. Zujewski J, Horak ID, Bol CJ, et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor ZARNESTRA in advanced cancer. J Clin Oncol. 2000;18:927-941.
7. Punt CJ, van Maanen L, Bol CJ, Seifert WF, Wagener DJ. Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor ZARNESTRA in patients with advanced solid tumors. Anti-Cancer Drugs. 2001;12:193-197.
8. Crul M, de Klerk GJ, Swart M, et al. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor ZARNESTRA in advanced cancer. J Clin Oncol. 2002;20:2726-2735.
9. Massiere F. Evaluation of the Cytotoxicity of R115777 and R208176 Using Human Hepatocyte Cultures. Raritan, NJ: Johnson & Johnson Pharmaceutical Research and Development, Nonclinical Pharmacokinetics Report, 2001; EDMS-PSDB-1688207.
10. 14C-R115777 and on the Effect of R115777 on the Metabolism of Specific Human Cytochrome P-450 Probe Substrates. Raritan, NJ: Johnson & Johnson Pharmaceutical Research and Development, Nonclinical Pharmacokinetics Report, 1998; N134077.
11. End D, Devine A. Antiproliferative Effects of R130525 in T24 H-ras Transformed NIH 3T3 Fibroblast Cells in Culture. Raritan, NJ: Johnson & Johnson Pharmaceutical Research and Development, Nonclinical Research Report, 1998; N134101.
12. End D, Skrzat S. Biochemical and Biological Activity of an Enantiomer (R115776) and Metabolites (R110127, R113197, R104209 and R101763) of the Farnesyl Protein Transferase Inhibitor R115777. Raritan, NJ: Johnson & Johnson Pharmaceutical Research and Development, Nonclinical Research Report, 2001; EDMS-BEBE-2571027.
13. Garner RC, Goris I, Laenen AAE, et al. Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study-experience with C-14-labeled (R)-6-[amino (4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4- (3-chlorophenyl)-1-methyl-2(1H)-quinolinone (ZARNESTRA), a farnesyl transferase inhibitor. Drug Metab Dispos. 2002;30:823-830.
14. Vanhoutte F, Bol K, Delor I, Janssens L, van Hest A, van Peer A. Pharmacokinetics, Absolute Oral Bioavailability and Safety of Tipifarnib Following Single Intravenous and Oral Dosing of Tipifarnib in Healthy Volunteers. Raritan, NJ: Johnson & Johnson Pharmaceutical Research and Development, Clinical Research Report, 2000; N149428.
15. National Cancer Institute of Canada. CTG Expanded Common Toxicity Criteria. Rev. ed. Kingston, Ontario: National Cancer Institute of Canada, Clinical Trial Group; 1994.
16. van Dun J, Maes S, Hendricks J, Mannens G, Janicot M. Effects of the N-glucuronide Metabolite of Tipifarnib on Farnesyl Protein Transferase Activity In Vitro. Raritan, NJ: Johnson & Johnson Pharmaceutical Research and Development, Nonclinical Research Report, 2001; EDMS-BEBE-3135179.
17. Snel W. The Plasma Protein Binding and Blood Distribution of Tipifarnib in Animals and Man. Raritan, NJ: Johnson & Johnson Pharmaceutical Research and Development, Nonclinical Research Report, 2001; EDMS-BEBE-1779296.